CENTRUS ENERGY CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CENTRUS ENERGY CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $123.60M | Mar 16, 2015 |
| FY2014 | Sep 30, 2014 | $390.50M | Mar 16, 2015 |
| FY2013 | Dec 31, 2013 | $398.50M | Mar 31, 2014 |
| FY2013 | Sep 30, 2013 | $303.80M | Mar 31, 2014 |
| FY2013 | Jun 30, 2013 | $284.80M | Mar 31, 2014 |
| FY2013 | Mar 31, 2013 | $320.40M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $403.30M | Mar 31, 2014 |
| FY2013 | Sep 30, 2012 | $563.00M | Mar 31, 2014 |
| FY2013 | Jun 30, 2012 | $353.80M | Mar 31, 2014 |
| FY2013 | Mar 31, 2012 | $542.00M | Mar 31, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.70M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $442.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $320.20M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $293.80M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $298.30M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $247.20M | Feb 22, 2023 |
| FY2020 | Dec 31, 2019 | $209.70M | Mar 22, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.50M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $111.50M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $112.10M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $117.90M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $114.50M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $35.00M | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | ($800.0K) | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | $43.80M | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | $19.60M | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | $6.80M | Mar 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.80M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $73.20M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $84.40M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $52.20M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $175.00M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $16.40M | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | ($7.00M) | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | $33.70M | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | $11.30M | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | ($2.80M) | Mar 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.20M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $48.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $52.40M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $59.70M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $68.30M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $20.60M | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | ($9.50M) | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | $31.00M | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | $8.90M | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | ($6.70M) | Mar 22, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.90M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $17.20M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $14.20M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $14.80M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $2.10M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $1.00M | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | $200.0K | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | $700.0K | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | $900.0K | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | $1.60M | Mar 22, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.20M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $35.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $36.90M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $33.90M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $36.00M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $10.40M | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | $6.70M | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | $10.40M | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | $8.50M | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | $9.20M | Mar 22, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $37.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $9.10M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $20.60M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $50.00M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $67.10M | Feb 22, 2023 |
| FY2020 | Dec 31, 2019 | $11.30M | Mar 22, 2021 |
| FY2013 | Dec 31, 2013 | $81.20M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $142.90M | Mar 31, 2014 |
| FY2013 | Dec 31, 2011 | $56.30M | Mar 31, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.70M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $4.10M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.60M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $700.0K | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $1.20M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $1.40M | Feb 22, 2023 |
| FY2020 | Dec 31, 2019 | $100.0K | Mar 22, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.45B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.09B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $796.20M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $705.50M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $572.40M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $486.30M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $455.90M | Mar 22, 2021 |
| FY2014 | Dec 31, 2014 | $1.18B | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $1.71B | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $2.27B | Mar 31, 2014 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.68B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $932.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $763.90M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $779.60M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $714.30M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $806.90M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $792.80M | Mar 22, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $765.10M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $161.40M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $32.30M | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | ($74.10M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2021 | ($141.90M) | Feb 7, 2025 |
| FY2023 | Dec 31, 2020 | ($320.60M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2019 | ($336.90M) | Feb 22, 2023 |
| FY2020 | Dec 31, 2018 | ($321.90M) | Mar 22, 2021 |
| FY2013 | Dec 31, 2013 | ($458.20M) | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | ($472.90M) | Mar 31, 2014 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2014 | Mar 15, 2013 | $6.80M | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $6.80M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $6.80M | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $6.80M | Mar 14, 2012 |
| FY2010 | Dec 31, 2009 | $6.80M | Feb 24, 2011 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($76.30M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($149.50M) | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | ($233.90M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | ($284.60M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($407.70M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($405.00M) | Mar 22, 2021 |
| FY2013 | Dec 31, 2013 | ($1.52B) | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | ($1.36B) | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | ($161.20M) | Mar 18, 2013 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.96B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $671.40M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $201.20M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $179.90M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $193.80M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $152.00M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $130.70M | Mar 22, 2021 |
| FY2013 | Dec 31, 2013 | $314.20M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $292.90M | Mar 31, 2014 |
| FY2013 | Dec 31, 2011 | $37.60M | Mar 31, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $472.50M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $89.60M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $95.70M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $101.80M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $108.00M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $114.10M | Mar 22, 2021 |
| FY2014 | Dec 31, 2014 | $240.40M | Mar 16, 2015 |
| FY2014 | Sep 30, 2014 | $240.40M | Mar 16, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | 10 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | (2) | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | 3 | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 22, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | (2) | Mar 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 22, 2021 |
| FY2020 | Jun 30, 2020 | 3 | Mar 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 22, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 22, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | 4.99M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | 5.01M | Mar 31, 2014 |
| FY2013 | Dec 31, 2011 | 4.93M | Mar 31, 2014 |
| FY2010 | Dec 31, 2010 | 115.23M | Feb 24, 2011 |
| FY2010 | Dec 31, 2009 | 113.39M | Feb 24, 2011 |